Amsterdam Molecular Therapeutics (AMT) has entered into an agreement with Institut Pasteur, and a group of French research institutes (the “Consortium”) to support clinical development of a gene therapy to treat Sanfilippo B., a rare genetic disease affecting newborn children that leads to progressive neuronal degeneration and death. Institut Pasteur will lead the development program and sponsor the initial Phase I/II study of a gene therapy to replace an enzyme (alpha-N-acetylgl...